Chlorthalidone Recalled: Over 11,000 Bottles of Blood Pressure Medication Pulled From Shelves
Your blood pressure medication might not actually be working. That’s the alarming possibility behind a nationwide recall of chlorthalidone tablets, a widely prescribed diuretic used to treat hypertension and fluid retention. Inventia Healthcare Limited recalled 11,460 bottles of Chlorthalidone Tablets USP, 25 mg, due to a dissolution failure, potentially impacting the tablets’ effectiveness in treating high blood pressure and fluid retention. The recall was initiated June 5, 2026, and the news broke nationally this week.
If you take chlorthalidone, here’s everything you need to know before you touch that pill bottle.
What Is Chlorthalidone and Why Does This Recall Matter?
Chlorthalidone is a diuretic or “water pill” used to treat hypertension and reduce excess fluid caused by heart, kidney or liver disease. It works by prompting the kidneys to flush excess salt and water out of the body, which lowers blood volume and, in turn, blood pressure. It’s one of the oldest thiazide-type diuretics on the market, reliable enough that it’s frequently the generic of choice for patients managing cardiovascular risk.
That’s exactly what makes this recall so consequential. We’re not talking about a medication that people take occasionally. Chlorthalidone is a daily maintenance drug. If the tablets aren’t dissolving correctly, patients may think they’re protected when they aren’t.
What Went Wrong: Failed Dissolution Specifications
The phrase the FDA uses here is “failed dissolution specifications,” and it sounds technical enough to gloss over. Don’t.
Dissolution testing evaluates how well a drug dissolves and releases its active ingredients when placed in liquid. This helps to assess the performance and quality of different drug formulations, as well as to ensure consistency in drug release between different batches.
In plain terms, according to the FDA, failure to meet specifications could mean a less effective medication or incorrect dosage. The tablets tested during regulatory review did not break down the way they’re supposed to. Whether any patient has already experienced reduced efficacy from these specific batches remains unclear.
The FDA has classified this recall as a Class II. The three classes range from Class I, the most serious, which involves a potentially life-threatening hazard, to Class III, which is reserved for labeling errors, incorrect expiration dates and other issues that don’t present an obvious threat to the user’s health.
Who Made These Pills and What Batches Are Affected?
The pills were manufactured by Inventia Healthcare Limited in India and distributed by Rising Pharma Holdings, Inc. in East Brunswick, New Jersey.
The recall affects 100-tablet bottles marked batch RISA24001 and 1,000-tablet bottles marked batch RISB24002. The pills have an expiration date of April 2027.
If you have a bottle at home, check those batch numbers immediately. Both the 100-count and 1,000-count bottle sizes sold nationwide are included in this recall.
This Is the Second Blood Pressure Recall in a Month
Here’s the detail most coverage is burying: this isn’t an isolated incident. The recall comes roughly a month after another blood pressure medication was recalled for failed dissolution specifications. Amlodipine and Olmesartan Medoxomil tablets were recalled in May and classified as a Class II recall.
Two dissolution failures on two different blood pressure medications within 30 days. That pattern deserves attention. It points to systemic quality control problems at the manufacturing level, not random bad luck. And it raises a bigger question that patients and prescribers should be asking: how many more batches with borderline dissolution performance never get caught?
The FDA’s enforcement infrastructure depends heavily on manufacturers’ self-reporting and post-market testing. A 2025 study found that the risk of serious adverse events was 54.3% higher with generics made in India as compared with those made in the United States. And the longer a drug has been available in generic form, the greater the difference in safety risk between its U.S.- and India-made forms.
This recall was initiated in India-based manufacturing. Make of that what you will.
What Patients Should Do Right Now
Stop scrolling and do these three things:
Check your bottle. Look for batch numbers RISA24001 (100-count) or RISB24002 (1,000-count) with an April 2027 expiration date. If yours matches, you’re in the affected pool.
Do not stop your medication cold turkey. Stopping a blood pressure drug abruptly can cause rebound hypertension, which carries its own serious cardiovascular risks. Call your pharmacist or doctor first.
Contact your pharmacist. They receive FDA recall notices directly and can tell you instantly whether your specific batch is affected and help coordinate a replacement prescription from a compliant lot.
You can also report any unexpected symptoms to the FDA’s MedWatch program at FDA.gov.
The Bottom Line
The chlorthalidone recall isn’t a signal to panic. It is a signal to pay attention. Check your batch number, call your pharmacist, and keep taking your medication until a healthcare provider tells you otherwise. Hypertension doesn’t take a day off just because your pill bottle is under scrutiny.
FAQ
Q: What is the chlorthalidone recall about?
The FDA is recalling 11,460 bottles of chlorthalidone tablets, USP, 25 mg, manufactured by Inventia Healthcare Limited, because the tablets failed dissolution specifications — meaning they may not dissolve properly and could be less effective than intended.
Q: Which batch numbers are affected by the chlorthalidone recall?
The two affected batches are RISA24001 (100-tablet bottles) and RISB24002 (1,000-tablet bottles), both with an expiration date of April 2027.
Q: Who distributed the recalled chlorthalidone?
Rising Pharma Holdings, Inc., based in East Brunswick, New Jersey, distributed the recalled tablets nationwide. The manufacturer is Inventia Healthcare Limited of India.
Q: Is the chlorthalidone recall dangerous?
Dissolution failure means the drug may be less effective, not that it is acutely toxic.
Q: Should I stop taking chlorthalidone?
No. Do not stop a blood pressure medication without talking to your doctor or pharmacist. Abruptly stopping can cause blood pressure to spike. Contact your pharmacy first to determine whether your specific batch is affected and get a safe replacement.
Q: How do I report a side effect from a recalled medication?
Report any unexpected symptoms through the FDA’s MedWatch Safety Information and Adverse Event Reporting Program at FDA.gov/medwatch.
